 Christine Fisher
Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 14 | 2024 | 229 | 4.520 |
Why?
| | Brachytherapy | 13 | 2023 | 104 | 4.230 |
Why?
| | Endometrial Neoplasms | 9 | 2025 | 162 | 2.070 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 7 | 2024 | 124 | 1.780 |
Why?
| | Breast Neoplasms | 20 | 2024 | 2127 | 1.750 |
Why?
| | Hysterectomy | 5 | 2019 | 117 | 1.730 |
Why?
| | Uterine Neoplasms | 5 | 2023 | 101 | 1.560 |
Why?
| | Carcinosarcoma | 3 | 2023 | 16 | 1.380 |
Why?
| | Genital Neoplasms, Female | 4 | 2024 | 82 | 1.050 |
Why?
| | Databases, Factual | 5 | 2021 | 1266 | 1.030 |
Why?
| | Radiation Oncology | 5 | 2022 | 75 | 1.010 |
Why?
| | Neoplasm Staging | 17 | 2021 | 1280 | 0.920 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2024 | 129 | 0.880 |
Why?
| | Radiosurgery | 4 | 2023 | 320 | 0.860 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 54 | 0.790 |
Why?
| | Chemoradiotherapy | 4 | 2019 | 208 | 0.780 |
Why?
| | Healthcare Disparities | 2 | 2018 | 574 | 0.720 |
Why?
| | Radiotherapy, Adjuvant | 6 | 2019 | 208 | 0.700 |
Why?
| | Simulation Training | 1 | 2021 | 81 | 0.680 |
Why?
| | Margins of Excision | 1 | 2019 | 37 | 0.610 |
Why?
| | Female | 55 | 2025 | 68494 | 0.600 |
Why?
| | Insurance, Health | 2 | 2018 | 265 | 0.600 |
Why?
| | Aquaporin 4 | 1 | 2019 | 95 | 0.590 |
Why?
| | Necrosis | 1 | 2019 | 231 | 0.590 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 181 | 0.530 |
Why?
| | Perioperative Care | 1 | 2018 | 151 | 0.530 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 32 | 0.520 |
Why?
| | Insurance Coverage | 1 | 2018 | 218 | 0.520 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1554 | 0.520 |
Why?
| | Aged | 25 | 2024 | 21997 | 0.510 |
Why?
| | Standard of Care | 1 | 2016 | 71 | 0.500 |
Why?
| | Middle Aged | 29 | 2024 | 31050 | 0.490 |
Why?
| | SEER Program | 6 | 2021 | 202 | 0.480 |
Why?
| | Adenocarcinoma | 4 | 2024 | 891 | 0.460 |
Why?
| | Neoplasms | 3 | 2022 | 2442 | 0.460 |
Why?
| | Humans | 60 | 2025 | 129144 | 0.460 |
Why?
| | Survival Rate | 7 | 2019 | 1869 | 0.460 |
Why?
| | Health Plan Implementation | 1 | 2015 | 137 | 0.450 |
Why?
| | Medical Errors | 1 | 2015 | 103 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2021 | 954 | 0.450 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2014 | 80 | 0.440 |
Why?
| | Radiotherapy Dosage | 5 | 2023 | 251 | 0.430 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 317 | 0.420 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 507 | 0.410 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1336 | 0.410 |
Why?
| | Carcinoma | 1 | 2014 | 214 | 0.400 |
Why?
| | Pelvis | 1 | 2013 | 104 | 0.400 |
Why?
| | Combined Modality Therapy | 6 | 2020 | 1198 | 0.380 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1266 | 0.380 |
Why?
| | Internship and Residency | 1 | 2021 | 1046 | 0.380 |
Why?
| | Prostatectomy | 1 | 2012 | 102 | 0.380 |
Why?
| | Receptor, ErbB-2 | 5 | 2021 | 325 | 0.380 |
Why?
| | Vulvar Neoplasms | 2 | 2024 | 12 | 0.360 |
Why?
| | Carcinoma, Endometrioid | 2 | 2023 | 44 | 0.350 |
Why?
| | Mastectomy, Segmental | 4 | 2020 | 85 | 0.330 |
Why?
| | Adult | 21 | 2024 | 35469 | 0.330 |
Why?
| | United States | 13 | 2022 | 13825 | 0.330 |
Why?
| | Mutation | 3 | 2023 | 3705 | 0.330 |
Why?
| | Lymphatic Metastasis | 3 | 2021 | 320 | 0.310 |
Why?
| | Re-Irradiation | 2 | 2020 | 8 | 0.300 |
Why?
| | Aged, 80 and over | 12 | 2024 | 7037 | 0.300 |
Why?
| | Cancer Pain | 2 | 2018 | 26 | 0.280 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 908 | 0.270 |
Why?
| | Treatment Outcome | 9 | 2023 | 10192 | 0.270 |
Why?
| | Prostatic Neoplasms | 2 | 2012 | 996 | 0.270 |
Why?
| | Retrospective Studies | 14 | 2024 | 14450 | 0.260 |
Why?
| | Sarcoma | 2 | 2021 | 175 | 0.260 |
Why?
| | Mastectomy | 3 | 2020 | 131 | 0.250 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2021 | 377 | 0.240 |
Why?
| | Neoadjuvant Therapy | 2 | 2018 | 379 | 0.230 |
Why?
| | Consensus | 2 | 2024 | 615 | 0.230 |
Why?
| | Regression Analysis | 2 | 2019 | 992 | 0.220 |
Why?
| | Young Adult | 8 | 2021 | 12385 | 0.220 |
Why?
| | Papillomavirus Infections | 2 | 2019 | 296 | 0.220 |
Why?
| | Follow-Up Studies | 4 | 2018 | 4882 | 0.220 |
Why?
| | Prognosis | 6 | 2023 | 3766 | 0.220 |
Why?
| | Medical Oncology | 4 | 2019 | 268 | 0.220 |
Why?
| | Carcinoma, Renal Cell | 2 | 2015 | 179 | 0.210 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 279 | 0.210 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2023 | 13 | 0.210 |
Why?
| | Kaplan-Meier Estimate | 4 | 2021 | 851 | 0.200 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 146 | 0.200 |
Why?
| | Hodgkin Disease | 2 | 2016 | 134 | 0.200 |
Why?
| | Brain Neoplasms | 2 | 2023 | 1143 | 0.200 |
Why?
| | Hydrocephalus | 1 | 2023 | 102 | 0.190 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 241 | 0.190 |
Why?
| | beta Catenin | 2 | 2023 | 225 | 0.180 |
Why?
| | Kidney Neoplasms | 2 | 2015 | 347 | 0.180 |
Why?
| | Veterans | 2 | 2022 | 1374 | 0.180 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 625 | 0.170 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 32 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3386 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 485 | 0.170 |
Why?
| | Benzodiazepines | 1 | 2021 | 134 | 0.160 |
Why?
| | Immunohistochemistry | 1 | 2023 | 1678 | 0.160 |
Why?
| | Lymph Nodes | 1 | 2021 | 470 | 0.150 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2021 | 193 | 0.150 |
Why?
| | Referral and Consultation | 1 | 2024 | 726 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1496 | 0.150 |
Why?
| | Pain Management | 2 | 2018 | 324 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 757 | 0.140 |
Why?
| | Relative Biological Effectiveness | 1 | 2017 | 3 | 0.140 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1197 | 0.140 |
Why?
| | Adolescent | 5 | 2019 | 20297 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 69 | 0.130 |
Why?
| | Machine Learning | 1 | 2021 | 442 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2024 | 2511 | 0.130 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 71 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 879 | 0.130 |
Why?
| | Propensity Score | 1 | 2018 | 263 | 0.130 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 2045 | 0.130 |
Why?
| | Breast | 1 | 2017 | 152 | 0.130 |
Why?
| | Logistic Models | 2 | 2018 | 1982 | 0.130 |
Why?
| | Radiotherapy Setup Errors | 1 | 2015 | 3 | 0.120 |
Why?
| | Radiation Injuries | 1 | 2017 | 135 | 0.120 |
Why?
| | Neoplasm Grading | 4 | 2019 | 282 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 106 | 0.120 |
Why?
| | Quality Control | 1 | 2015 | 163 | 0.120 |
Why?
| | Curriculum | 1 | 2021 | 909 | 0.120 |
Why?
| | Medically Uninsured | 1 | 2015 | 126 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 209 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 859 | 0.120 |
Why?
| | Risk Factors | 6 | 2020 | 9740 | 0.120 |
Why?
| | Radiation Tolerance | 1 | 2015 | 98 | 0.110 |
Why?
| | Checklist | 1 | 2015 | 92 | 0.110 |
Why?
| | Clinical Competence | 1 | 2021 | 1013 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 767 | 0.110 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 111 | 0.110 |
Why?
| | Cancer Vaccines | 2 | 2005 | 164 | 0.110 |
Why?
| | Internet | 1 | 2018 | 615 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2019 | 3372 | 0.110 |
Why?
| | Breast Neoplasms, Male | 1 | 2013 | 29 | 0.110 |
Why?
| | Tumor Burden | 1 | 2014 | 286 | 0.110 |
Why?
| | Skin Neoplasms | 2 | 2024 | 824 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1363 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1683 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2017 | 525 | 0.100 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1208 | 0.100 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 481 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 229 | 0.100 |
Why?
| | Biomarkers, Tumor | 4 | 2023 | 1161 | 0.100 |
Why?
| | Patient Safety | 1 | 2015 | 285 | 0.100 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 33 | 0.090 |
Why?
| | Texas | 1 | 2012 | 228 | 0.090 |
Why?
| | Male | 12 | 2024 | 63456 | 0.090 |
Why?
| | DNA Polymerase II | 2 | 2023 | 38 | 0.090 |
Why?
| | Medicaid | 1 | 2015 | 431 | 0.090 |
Why?
| | Peptide Fragments | 2 | 2005 | 692 | 0.090 |
Why?
| | Registries | 1 | 2018 | 1895 | 0.090 |
Why?
| | Disease Management | 1 | 2014 | 588 | 0.090 |
Why?
| | Liver Neoplasms | 1 | 2015 | 637 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2340 | 0.080 |
Why?
| | Age Factors | 1 | 2017 | 3140 | 0.080 |
Why?
| | Cohort Studies | 3 | 2021 | 5408 | 0.080 |
Why?
| | Quality Indicators, Health Care | 2 | 2022 | 298 | 0.080 |
Why?
| | Survival Analysis | 1 | 2012 | 1268 | 0.080 |
Why?
| | Melanoma | 1 | 2015 | 729 | 0.080 |
Why?
| | Risk Assessment | 2 | 2020 | 3231 | 0.070 |
Why?
| | Opioid-Related Disorders | 3 | 2021 | 483 | 0.070 |
Why?
| | Fertility Preservation | 2 | 2019 | 37 | 0.070 |
Why?
| | Epidemics | 2 | 2018 | 81 | 0.070 |
Why?
| | Medicare | 2 | 2021 | 706 | 0.060 |
Why?
| | Prospective Studies | 4 | 2023 | 7117 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2554 | 0.060 |
Why?
| | Gynecology | 2 | 2018 | 174 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 147 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2005 | 160 | 0.060 |
Why?
| | Paget Disease, Extramammary | 1 | 2024 | 4 | 0.060 |
Why?
| | Radiotherapy | 2 | 2015 | 185 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 47 | 0.050 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 33 | 0.050 |
Why?
| | Aromatase | 1 | 2023 | 31 | 0.050 |
Why?
| | Needles | 1 | 2023 | 57 | 0.050 |
Why?
| | Time Factors | 4 | 2020 | 6541 | 0.050 |
Why?
| | Receptors, Estrogen | 2 | 2016 | 421 | 0.050 |
Why?
| | Anthracyclines | 1 | 2021 | 49 | 0.050 |
Why?
| | Taxoids | 1 | 2021 | 98 | 0.050 |
Why?
| | Precision Medicine | 1 | 2025 | 386 | 0.040 |
Why?
| | Trastuzumab | 1 | 2021 | 100 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 50 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 178 | 0.040 |
Why?
| | Estrogens | 1 | 2023 | 346 | 0.040 |
Why?
| | Quinolines | 1 | 2021 | 156 | 0.040 |
Why?
| | Radiometry | 1 | 2019 | 47 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 37 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 41 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 32 | 0.040 |
Why?
| | Cervix Uteri | 1 | 2019 | 49 | 0.040 |
Why?
| | Papanicolaou Test | 1 | 2019 | 41 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 34 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 263 | 0.040 |
Why?
| | Papillomaviridae | 1 | 2019 | 113 | 0.040 |
Why?
| | India | 1 | 2018 | 170 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2022 | 623 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 607 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 161 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 512 | 0.040 |
Why?
| | Vagina | 1 | 2019 | 174 | 0.040 |
Why?
| | Organs at Risk | 1 | 2017 | 31 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1943 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 419 | 0.030 |
Why?
| | Skin Ulcer | 1 | 2015 | 13 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 34 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 757 | 0.030 |
Why?
| | HLA-A2 Antigen | 2 | 2005 | 48 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 35 | 0.030 |
Why?
| | Societies, Medical | 1 | 2019 | 744 | 0.030 |
Why?
| | Reoperation | 1 | 2017 | 541 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 520 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1017 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 301 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 712 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2622 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1084 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 316 | 0.030 |
Why?
| | Age Distribution | 1 | 2013 | 372 | 0.030 |
Why?
| | Sex Distribution | 1 | 2013 | 359 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1116 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1003 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1544 | 0.020 |
Why?
| | Skin | 1 | 2017 | 726 | 0.020 |
Why?
| | Vinblastine | 1 | 2011 | 70 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 341 | 0.020 |
Why?
| | Dacarbazine | 1 | 2011 | 93 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1148 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 5382 | 0.020 |
Why?
| | Remission Induction | 1 | 2011 | 271 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1288 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4402 | 0.020 |
Why?
| | Bleomycin | 1 | 2011 | 242 | 0.020 |
Why?
| | Doxorubicin | 1 | 2011 | 328 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1613 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1964 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2272 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2635 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 41 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2005 | 220 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2005 | 169 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5044 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2005 | 103 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2005 | 545 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2005 | 772 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2005 | 854 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3186 | 0.010 |
Why?
| | Child | 1 | 2013 | 20768 | 0.010 |
Why?
|
|
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|